Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Atorvastatin111 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00346 | 35126843 | World J Hepatol | Is there a role of lipid-lowering therapies in the management of fatty liver disease? | 2022 | Details |
| A00554 | 35048107 | Eur Heart J | Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. | 2022 | Details |
| A01124 | 34862975 | FASEB J | Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. | 2022 | Details |
| A02213 | 34458376 | J Immunol Res | Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway. | 2021 | Details |
| A02878 | 34208774 | Int J Mol Sci | Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. | 2021 | Details |
| A03371 | 34027116 | Clin Exp Hepatol | Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A03404 | 34014280 | Dis Model Mech | Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH. | 2021 | Details |
| A05750 | 33132768 | ScientificWorldJournal | Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin. | 2020 | Details |
| A05930 | 33072533 | Adv Pharm Bull | The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. | 2020 | Details |
| A05967 | 33059580 | Curr Vasc Pharmacol | Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role? | 2021 | Details |
| A06936 | 32694178 | Gut | Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. | 2020 | Details |
| A06965 | 32684739 | World J Gastroenterol | Medications in type-2 diabetics and their association with liver fibrosis. | 2020 | Details |
| A07152 | 32598715 | Ter Arkh | [Evaluation of the effectiveness of differentiated therapy of non-alcoholic fatty liver disease]. | 2020 | Details |
| A08211 | 32202947 | Arch Physiol Biochem | All-Trans Retinoic Acid (atRA) effectively improves liver steatosis in a rabbit model of high fat induced liver steatosis. | 2020 | Details |
| A08455 | 32104276 | Exp Ther Med | Atorvastatin promotes AMPK signaling to protect against high fat diet-induced non-alcoholic fatty liver in golden hamsters. | 2020 | Details |
| A09006 | 31907123 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | [Intervention of Catalpol on High-fat Diet Induced Nonalcoholic Fatty Liver Disease in Mice]. | 2019 | Details |
| A09079 | 31882668 | Sci Rep | Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH. | 2019 | Details |
| A09433 | 31752351 | Nutrients | Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model. | 2019 | Details |
| A10276 | 31402538 | Liver Int | CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. | 2019 | Details |
| A11279 | 30961499 | Curr Vasc Pharmacol | Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. | 2020 | Details |
| A11998 | 30652643 | Curr Pharm Des | The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A12474 | 30431378 | Curr Med Res Opin | Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial. | 2018 | Details |
| A13598 | 29887885 | Adv Pharmacol Sci | Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men. | 2018 | Details |
| A13901 | 29702089 | Chem Biol Interact | Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. | 2018 | Details |
| A14824 | 29217477 | Biochim Biophys Acta Mol Cell Biol Lipids | Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. | 2017 | Details |
| A15054 | 29117763 | Toxicol Mech Methods | Pilose antler peptide attenuates high-fat-diet-induced liver injury. | 2017 | Details |
| A15424 | 28919478 | Biochim Biophys Acta Mol Cell Biol Lipids | Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. | 2017 | Details |
| A15606 | 28815679 | Clin Exp Pharmacol Physiol | (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease. | 2017 | Details |
| A15871 | 28676027 | Curr Vasc Pharmacol | The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options? | 2018 | Details |
| A15876 | 28676019 | Curr Vasc Pharmacol | Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. | 2018 | Details |
| A15877 | 28676018 | Curr Vasc Pharmacol | Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? | 2018 | Details |
| A16062 | 28587208 | Mar Drugs | Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models. | 2017 | Details |
| A16109 | 28565851 | Exp Ther Med | Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. | 2017 | Details |
| A16163 | 28529649 | Theranostics | SAK-HV Triggered a Short-period Lipid-lowering Biotherapy Based on the Energy Model of Liver Proliferation via a Novel Pathway. | 2017 | Details |
| A16460 | 28375109 | Pak J Pharm Sci | Anti hyperlipidemic and hepatoprotective effects of native date fruit variety "Aseel" (Phoenix dactylifera). | 2016 | Details |
| A17506 | 27098507 | Diabetes Metab J | Statins Increase Mitochondrial and Peroxisomal Fatty Acid Oxidation in the Liver and Prevent Non-Alcoholic Steatohepatitis in Mice. | 2016 | Details |
| A19020 | 26817117 | Eksp Klin Gastroenterol | [COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE]. | 2015 | Details |
| A19267 | 26666731 | J Ethnopharmacol | The hepatoprotective effect of the combination use of Fructus Schisandrae with statin--A preclinical evaluation. | 2015 | Details |
| A19920 | 26265520 | Arch Iran Med | PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. | 2015 | Details |
| A20133 | 26134926 | Expert Opin Drug Saf | Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? | 2015 | Details |
| A20179 | 26104139 | Histol Histopathol | Effect of diet/atorvastatin on atherosclerotic lesions associated to nonalcoholic fatty liver disease in chickens. | 2015 | Details |
| A20712 | 25786512 | Liver Int | Acute atorvastatin is hepatoprotective against ischaemia-reperfusion injury in mice by modulating eNOS and microparticle formation. | 2015 | Details |
| A20841 | 25697114 | Med Hypotheses | Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH. | 2015 | Details |
| A21090 | 25541989 | PLoS One | LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study. | 2014 | Details |
| A21091 | 25541279 | Prostaglandins Leukot Essent Fatty Acids | Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis. | 2014 | Details |
| A21123 | 25528845 | Lik Sprava | [Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis]. | 2014 | Details |
| A21141 | 25520429 | J Lipid Res | Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. | 2014 | Details |
| A22050 | 24850606 | Georgian Med News | [Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis]. | 2014 | Details |
| A22171 | 24768901 | J Hepatol | Perilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte. | 2014 | Details |
| A22668 | 24374462 | Cochrane Database Syst Rev | Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. | 2013 | Details |
| A22672 | 24373179 | Diabetes Obes Metab | APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. | 2014 | Details |
| A22700 | 25796814 | Wiad Lek | Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis. | 2014 | Details |
| A22997 | 24127654 | Curr Med Res Opin | Are statins 'IDEAL' for non-alcoholic fatty liver disease? | 2013 | Details |
| A23354 | 23847661 | Arch Med Sci | Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. | 2013 | Details |
| A23768 | 23500152 | J Hepatol | Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. | 2013 | Details |
| A24188 | 23140546 | Curr Vasc Pharmacol | The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. | 2013 | Details |
| A24543 | 22770622 | Expert Opin Pharmacother | The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. | 2012 | Details |
| A24852 | 22432744 | J Gastroenterol Hepatol | Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation. | 2012 | Details |
| A24872 | 22418885 | Semin Liver Dis | Dyslipidemia in patients with nonalcoholic fatty liver disease. | 2012 | Details |
| A24973 | 22291824 | Arch Med Sci | Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. | 2011 | Details |
| A24997 | 22265683 | Dig Liver Dis | Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. | 2012 | Details |
| A25203 | 22096112 | Eur J Endocrinol | Recent advances in cardiovascular aspects of polycystic ovary syndrome. | 2011 | Details |
| A25299 | 21986643 | Curr Opin Lipidol | Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. | 2011 | Details |
| A25587 | 21684478 | Arab J Gastroenterol | Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. | 2011 | Details |
| A25955 | 21269482 | Lipids Health Dis | Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. | 2011 | Details |
| A26004 | 21218508 | Diabetes Metab Res Rev | Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. | 2011 | Details |
| A26007 | 21212755 | Am J Gastroenterol | Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required? | 2011 | Details |
| A26090 | 21122807 | Toxicol Appl Pharmacol | Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. | 2010 | Details |
| A26098 | 21109302 | Lancet | Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. | 2010 | Details |
| A26248 | 20842109 | Am J Gastroenterol | Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. | 2010 | Details |
| A26602 | 20112031 | J Gastroenterol | Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. | 2010 | Details |
| A26701 | 19932590 | Biomed Pharmacother | Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. | 2009 | Details |
| A27235 | 18936912 | Naunyn Schmiedebergs Arch Pharmacol | A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. | 2008 | Details |
| A27469 | 18330098 | Acta Gastroenterol Belg | Statins in hepatobiliary diseases: effects, indications and risks. | 2008 | Details |
| A27485 | 18302012 | Inflammation | Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. | 2008 | Details |
| A27970 | 16842328 | Liver Int | Intracellular retention of hepatic serpins caused by severe hyperlipidemia. | 2006 | Details |
| A28016 | 16709309 | Curr Med Res Opin | Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. | 2006 | Details |
| A28024 | 16696815 | Aliment Pharmacol Ther | A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. | 2006 | Details |
| A28376 | 15333967 | Indian J Gastroenterol | Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. | 2004 | Details |
| A28459 | 14585234 | Curr Treat Options Gastroenterol | Treatment of Nonalcoholic Fatty Liver Disease. | 2003 | Details |
| A30133 | 32924771 | J Pharm Pract | Statin Associated Autoimmune Myonecrosis: Case Report With Delayed Onset and Treatment Challenges. | 2020 | Details |
| A30156 | 32882802 | Antioxidants (Basel) | Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation. | 2020 | Details |
| A36094 | 19013295 | Metabolism | Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. | 2008 | Details |
| A36711 | 17410287 | J Gastrointestin Liver Dis | Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. | 2007 | Details |
| A37781 | 14679419 | Can J Gastroenterol | Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. | 2003 | Details |
| A43781 | 30894877 | Evid Based Complement Alternat Med | BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE-/- Mice. | 2019 | Details |
| A44438 | 28628040 | J Clin Invest | Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity. | 2017 | Details |
| A44450 | 28596414 | Am J Physiol Gastrointest Liver Physiol | Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal? | 2017 | Details |
| A44650 | 27807313 | Hong Kong Med J | Effect of combined use of Fructus Schisandrae and statin on high-fat-diet-induced metabolic syndrome in rats. | 2016 | Details |
| A44758 | 27419149 | Open Forum Infect Dis | Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus. | 2016 | Details |
| A45721 | 23099228 | Dig Liver Dis | Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". | 2012 | Details |
| A45725 | 23058851 | Dig Liver Dis | Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". | 2012 | Details |
| A45758 | 22917635 | Dig Liver Dis | Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". | 2012 | Details |
| A45759 | 22909420 | Dig Liver Dis | Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". | 2012 | Details |
| A45773 | 22823912 | J Gastroenterol Hepatol | Enhancing organ pool by statins: is this the future? | 2012 | Details |
| A45797 | 22686718 | Natl Med J India | Atorvastatin and antioxidants: the remedy for non-alcoholic fatty liver disease? | 2012 | Details |
| A45831 | 22487461 | Dig Liver Dis | If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis? | 2012 | Details |
| A46272 | 19877024 | Liver Transpl | Obesity, hyperlipidemia, and metabolic syndrome. | 2009 | Details |
| A46273 | 19875919 | Turk Kardiyol Dern Ars | The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. | 2009 | Details |
| A46743 | 15989845 | Med Clin (Barc) | [Medical management of primary nonalcoholic fatty liver disease]. | 2005 | Details |